Fortress Biotech, Inc. (FBIO)
2.03
-0.04
(-1.93%)
USD |
NASDAQ |
Oct 02, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Fortress Biotech EPS Diluted (Quarterly) : -0.0779 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0779 |
| March 31, 2026 | 2.821 |
| December 31, 2025 | -0.1976 |
| September 30, 2025 | 0.111 |
| June 30, 2025 | 0.4478 |
| March 31, 2025 | -0.4807 |
| December 31, 2024 | -0.3458 |
| September 30, 2024 | -0.7636 |
| June 30, 2024 | -0.7282 |
| March 31, 2024 | -1.041 |
| December 31, 2023 | -0.7478 |
| September 30, 2023 | -14.11 |
| June 30, 2023 | -3.649 |
| March 31, 2023 | -3.466 |
| December 31, 2022 | -3.658 |
| September 30, 2022 | -4.113 |
| June 30, 2022 | -3.610 |
| March 31, 2022 | -2.741 |
| December 31, 2021 | -4.668 |
| September 30, 2021 | -3.832 |
| June 30, 2021 | -0.6549 |
| March 31, 2021 | -1.637 |
| December 31, 2020 | -0.8372 |
| September 30, 2020 | -3.065 |
| June 30, 2020 | -2.913 |
| Date | Value |
|---|---|
| March 31, 2020 | -2.922 |
| December 31, 2019 | -3.139 |
| September 30, 2019 | -3.367 |
| June 30, 2019 | -3.657 |
| March 31, 2019 | 0.3272 |
| September 30, 2018 | -5.568 |
| June 30, 2018 | -7.473 |
| March 31, 2018 | -6.951 |
| December 31, 2017 | -3.063 |
| September 30, 2017 | -10.05 |
| June 30, 2017 | -6.45 |
| March 31, 2017 | -4.50 |
| December 31, 2016 | -5.343 |
| September 30, 2016 | -4.80 |
| June 30, 2016 | -4.65 |
| March 31, 2016 | -4.65 |
| December 31, 2015 | -4.50 |
| September 30, 2015 | -6.90 |
| June 30, 2015 | -2.40 |
| March 31, 2015 | -4.65 |
| December 31, 2014 | -1.50 |
| September 30, 2014 | -1.95 |
| June 30, 2014 | -1.95 |
| March 31, 2014 | -3.15 |
| December 31, 2013 | -4.05 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -0.0737 |
| Kura Oncology, Inc. | -0.769 |
| Spero Therapeutics, Inc. | -0.1648 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.602M |
| Revenue (Quarterly) | 18.72M |
| Total Expenses (Quarterly) | 19.19M |
| Enterprise Value | -33.69M |
| Gross Profit Margin (Quarterly) | 61.50% |
| Profit Margin (Quarterly) | 3.22% |
| Earnings Yield | 130.9% |
| Normalized Earnings Yield | 120.63 |